Myocardial Repair with Myc-Cyclin T1 mRNA in the failing human heart

• Research type

  Research Study

• Full title

  Myocardial Repair with Myc-Cyclin T1 mRNA in the failing human heart

• IRAS ID

  325359

• Contact name

  Stephen Large

• Contact email

  s.large@nhs.net

• Sponsor organisation

  Royal Papworth Hospital NHS Foundation Trust

• Duration of Study in the UK

  1 years, 0 months, 1 days

• Research summary

  Up to 37 million people suffer from heart failure worldwide. Despite significant advances in treatment over the last three decades, almost half of heart failure patients die within a year of hospital discharge with the majority within
  five years. Heart failure occurs when the heart cannot pump blood efficiently around the body. It’s usually due to the irreversible loss of heart muscle - a common result after a heart attack.
  Myc and Cyclin T1 mRNA leads to the formation of proteins (M-C) that coax the pre-existing heart cells to divide and form new heart cells to recover the contractile function of the failing heart. Messenger RNA or mRNA is the ‘middle man’ in the process by which genetic information contained in DNA is transferred to make proteins. We can stimulate M-C production in the heart by injecting Myc-Cyclin T1 mRNA into the damaged muscle. Pre-clinical studies have shown that injecting Myc-Cyclin T1 mRNA into areas of the damaged heart muscle can result in the formation of new heart cells. Encouragingly, these pre-clinical studies have shown improved cardiac function in the treated hearts.
  With advances in heart perfusion outside of the human body, known as the ‘heart in a box’ machine, we can now test this therapy in human hearts. In this research, we intend to test Myc-Cyclin T1 mRNA in three explanted recipient hearts, which are not suitable for clinical transplantation.
  If this study is successful, it will confirm that injecting Myc-Cyclin T1 mRNA into heart muscle leads to the production of M-C protein with subsequent production of new heart cells to recover the contractile function of the heart. This could significantly improve the treatment of heart failure and help millions of patients suffering from this disease.
  This study will be conducted in collaboration with the University of Cambridge and AstraZeneca, a Research-based Biopharmaceutical Company

• REC name

  West Midlands - Black Country Research Ethics Committee

• REC reference

  23/WM/0236

• Date of REC Opinion

  25 Jan 2024

• REC opinion

  Further Information Favourable Opinion